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Abstract
In the last decade, the finding that somatic cells can be reprogrammed into induced 
 pluripotent stem cells (iPSCs) leads to a great improvement of research involving the use 
of differentiated stem cells as model of diseases. In the field of neurodegeneration, iPSC 
technology allowed to culture in vitro all the types of patient-specific neurons, not only 
helping the discovery of diseases’ etiopathology but also testing new drugs with a per-
sonalized medicine approach. Moreover, iPSCs can be combined with the 3D bioprinting 
technology, allowing physiological cell-to-cell interactions, given by a combination of sev-
eral biomaterials, scaffolds, and cells. This technology combines bioplotter and biomateri-
als which can encapsulate several types of cells, e.g., iPSCs or differentiated neurons, to 
develop an innovative cellular model. iPSCs and 3D cell cultures’ technologies represent 
the first step to obtain a more reliable model, like an organoid to facilitate neurodegenera-
tive diseases’ investigation.
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1. Introduction
Stem cells represent an unlimited cell source because of their property of self-renewal, and they 
can also differentiate into almost all adult cell types thanks to their pluripotency characteristic 
[1]. One of the main problems of stem cell research was the invasively harvesting techniques, 
such as through bone marrow, adipose tissue extraction by liposuction, or blood apheresis 
[2]. In 2006, the discovery that adult somatic cells can be reprogrammed into the so-called 
induced pluripotent stem cells (iPSCs) has allowed to generate stem cell lines with minimally 
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invasive techniques, like skin biopsy or, more recently, blood withdrawal [3]. These recent 
findings has led to an outstanding increase in disease mechanisms and drug screening studies 
involving stem cells, in particular for neurodegenerative diseases because of the impossibility 
to obtain neural cells from patients. The ability to reprogram patient-specific cells also opens 
new opportunities for the personalized medicine approach of drug discovery. Moreover, the 
development of 3D bioprinting provided a useful tool to generate innovative cell cultures, 
permitting to have a 3D model in which cells can be disposed with a controlled manner and 
where they can grow in a tissue-like structures [4]. Obviously, 3D bioprinting opened new 
possibilities in the field of tissue engineering, but it can be helpful also for disease modeling. 
In fact, the generation of a 3D scaffold that can resemble the human tissues will permit to 
study neurodegenerative diseases in the so-called brain in dish. Finally, the combination of 3D 
bioprinting technique with iPSC technology will permit to develop one of the most realistic 
and reliable in vitro cell cultures, permitting to study organoids with patients’ differentiated 
cells, leading to a personalized medicine approach in drug testing.
2. Stem cells
Stem cell research is considered one of the most promising areas in cell biology and regenera-
tive medicine due to stem cells’ unique properties of self-renewing and differentiation into 
all types of cells. These cells represent nowadays the main tool in the regenerative medicine 
field because they permit to generate cells needed for transplantation in several degenerative 
diseases [1], such as rheumatoid arthritis [5], diabetes mellitus [6], heart failure [7], liver dis-
eases [8], and neurological disorders [9–11]. Moreover, stem cells represent an important tool 
for modeling human diseases, in particular for diseases that affect cells that cannot be easily 
collected and cultivated. One of the biggest issues in the study of neurodegenerative diseases 
is the lack of good cellular models that recapitulate the mechanisms underlying their patho-
physiology, and in the last decade, stem cells played a major role in the study of these diseases.
2.1. Embryonic stem cells
The first evidence that human stem cells, called human embryonic stem cells (hESC), could be 
derived from a 5-day blastocyst was reported in 1998 by Thomson and colleagues [12]. ES cells 
have the ability to proliferate indefinitely and are considered pluripotent cells because they 
can differentiate into all three germ layers (ectoderm, mesoderm, and endoderm) and, thus, 
they can generate all the differentiated cells of the adult [13, 14]. Despite that they helped stem 
cell research, they also opened many controversies because ES cells are obtained from blasto-
cyst, killing the fertilized embryo that has the potential to generate a human being [15]. The 
big ethical issue on the use of hES cells encouraged researchers to understand the pathways 
underlying the staminality of this kind of cells.
2.2. Induced pluripotent stem cells
The research done with ES cells and the finding of their highly expressed transcription 
factors, permitted in 2006 to induce mouse’s fibroblasts to become pluripotent, by retro-
virus-mediated transduction with four transcription factors, i.e., Oct-3/4, Sox2, KLF4, and 
c-Myc [16]. The following studies allowed to improve the technique, permitting to generate 
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induced pluripotent stem cells (iPSCs) from adult human cells and to reprogram cells from 
several tissues [15]. Moreover, it is now possible to generate iPS cells by different transduc-
tion methods (Figure 1), using different viral and nonviral constructs, as well as integra-
tive and non-integrative system approaches [17]. The best methods to reprogram cells are 
the non-integrative methods, and the four main groups are available: non-integrative viral 
delivery, episomal delivery, RNA delivery, and protein delivery [18]. The establishment of 
human iPS cells has led to have an unlimited source of stem cells overcoming the ethical 
limit of hES cells. Moreover, iPSCs can be reprogrammed from any somatic cell line of the 
patients providing a way to study diseases’ mechanisms potentially for each patient, open-
ing to the so-called personalized medicine (Figure 1). Actually, many iPSCs’ lines have been 
generated from patients with neurodegenerative disease, like Alzheimer’s disease (AD) [19], 
Parkinson’s disease (PD) [20], amyotrophic lateral sclerosis (ALS) [21], and Huntington’s 
disease (HD) [22].
Figure 1. An overview of iPSC technology. Somatic cells can be taken from several sources, like the skin, blood, and 
urine. There are many reprogramming strategies, and the best ones are the non-integrative strategies. iPSCs can be 
differentiated into diverse cell lines that can be used for disease modeling, for drug discovery, and for cell replacement 
therapy (the image was taken from Sharma [23]).
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2.2.1. iPSCs in Alzheimer’s disease
Alzheimer’s disease (AD) is the most common form of dementia and is characterized by the 
progressive loss of memory and cognitive functions. The disease leads to a severe form of 
dementia that causes the death of the patient [24]. The two main hallmarks of the disease 
are the accumulation of amyloid beta (Aβ) plaques in the extracellular compartment and the 
aggregation of the tau protein in the intracellular compartment. Only 1–5% of AD cases have 
a genetic cause, while in the other cases, the real pathogenesis is still unknown [25].
Many groups used and performed several studies on in vitro models with neural and nonneu-
ronal cells derived from iPSCs. For example, higher susceptibility to Aβ1–Aβ42 oligomers was 
found in neuronal precursors derived from iPSC (iPSCs-NSCs) of a patient with a mutation in 
the PSEN1 gene (PSEN1-A246E mutation) compared to sporadic AD patient and healthy con-
trol [26]. The authors concluded that neurons derived from AD iPSCs could be effective in drug 
screening, to develop new treatments that protect cells from the toxicity of the Aβ peptides in the 
AD brain [26]. A similar result was obtained with iPSC-derived neurons of sporadic AD patients 
and of a patient carrying the pathogenic APP-E693Δ mutation. The study shows that these cell 
lines produce intracellular Aβ oligomers, resulting in a good cellular model of AD [27]. iPSCs 
can be used to find new potential biomarkers of the disease, as suggested by Shirotani et al. that 
developed an innovative method on neurons differentiated from iPSCs [28]. Moreover, induced 
fAD mutations by genome editing of neurons derived from healthy controls could resemble the 
pathophysiology of the disease. A decrease in endocytosis and soma-to-axon transcytosis of 
LDL was found in human neurons with expression of PSEN1ΔE9 induced with genome editing 
technology. To confirm the potential role of iPSCs in drug discovery, the authors reported that 
defects were rescued by β-secretase inhibition [29]. Another study reported the generation of 
an Alzheimer-related protein association network using iPSCs, demonstrating that they can be 
used as drug screening model and finding a reduction of tau protein after treatment with an 
inhibitor of γ-secretase [30]. For drug testing, it is important that iPSC-derived neurons are well 
differentiated, because it was seen that between early and late differentiation stages, cells have 
different susceptibilities to drugs [31]. Genome editing technology could be used also for muta-
tions’ correction, generating an isogenic control. For example, Pires and colleagues reported 
that A79V-iPSC line in combination of A79V-GC-iPSC line could be used to study pathological 
cellular phenotypes related to A79V mutation in PSEN [32]. Interestingly, the role of iPSCs in 
AD research was supported also by analyzing neurons derived from iPSCs of patients with 
Down syndrome that usually have a high risk of developing AD early. Authors found that 
such neural cells reproduce AD-like initial cellular hallmark, resulting useful for modeling this 
variant of AD [33]. Finally, also nonneuronal cells derived from iPSCs could be very useful 
in disease modeling and drug screening. Many pathological hallmarks were found aberrant 
in astrocytes derived from iPSCs of fAD and sAD patients suggesting that astrocytic atrophy 
could be a plausible mechanism for early cognitive impairment and thus opening new thera-
peutic strategies for AD intervention [34]. Another study reported changes in PSEN1-mutated 
iPSC-derived astrocytes, revealing the major role of such cells and confirming the importance to 
implement iPSC technology to support neurodegenerative diseases’ study [35].
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These researches suggest that iPSC-derived neurons from AD patients can help not only to 
unravel disease’s mechanisms but also to screen new treatment and to find new possible drug 
targets. Moreover, the authors hypothesize that gene correction is a useful tool to generate 
isogenic controls or to induce AD mutations in healthy controls. Finally, iPSCs can be dif-
ferentiated into glial cells, e.g., astrocytes, which in recent years gain an important role in the 
pathogenesis of several neurodegenerative diseases.
2.2.2. iPSCs in Parkinson’s disease
Parkinson’s disease (PD) is the second most common neurodegenerative disease after AD, 
with a prevalence of 1% out of the individuals over age 60 years and 4% of the population with 
an age over 85 years [36]. The most common mutations, found in about 10% of Parkinson’s 
patients, are present in six genes: SNCA, LRRK2, Parkin, PINK1, DJ-1, and ATP13A2 [37].
Usually, iPSCs are differentiated into dopaminergic (DA) neurons to model PD because the 
disease is characterized by the loss of DA neurons of the substantia nigra in the midbrain. Since 
monogenic mutations cause an idiopathic-like disease, diverse iPSC lines of patients with Parkin 
and PINK1 mutations (e.g., 2–4 exon deletions of Parkin and PINK1 Q456X) have been devel-
oped. It was seen that these cell lines present abnormalities in mitochondrial and dopamine 
homoeostasis, microtubular stability, and axonal outgrowth, resulting in an optimal model 
of the disease [38]. For example, many PD cell phenotypes, i.e., mitochondrial dysfunction, 
elevated α-synuclein, synaptic dysfunction, DA accumulation, and increased oxidative stress 
and ROS, were found in iPSC-DA neurons of patients carrying mutations in parkin (V324A) 
and PINK1 (Q456X) genes [39]. The role in neurons’ maturation of elevated α-synuclein caused 
by SNCA gene triplication was investigated in a cellular model obtained from PD-derived 
iPSCs. The author has claimed that such triplication leads to the impairment of differentiation 
and maturation of iPSCs [40]. An electrophysiological characterization of control dopaminer-
gic neurons derived from iPSC was provided by Hartfield and colleagues that confirmed that 
these cells have the physiological hallmarks of dopaminergic neurons previously reported only 
on rodent slice. These results suggested that such cells can be considered a useful tool for the 
physiological study of PD [41]. Moreover, several evidences suggest that PD is not only a brain 
disease but also a gastrointestinal disorder; thus, Son and colleagues differentiated iPSCs car-
rying an LRRK2 G2019S mutation in both neural and intestinal phenotypes, providing the first 
evidence that G2019S mutation causes significant changes in gene expression also in the intesti-
nal cells [42]. Interestingly, the pathologic phenotype was reversed in cortical neurons derived 
from iPSCs of patients mutated in SNCA using a small molecule found by yeast screening, 
opening new possibilities in drug screening and testing [43]. Finally, iPSCs have allowed an 
innovative co-culture of microglial cells and cortical neurons, displaying a unique cytokine 
profile impossible to obtain without iPSCs [44]. iPSCs were proposed to be used for tissue 
transplantation, and Kikuchi et al. achieved the transplantation of human iPS cell-derived 
dopaminergic neurons in a primate model of PD treated with MTPT. The authors reported an 
increase in spontaneous movement of the monkeys, demonstrating for the first time that such 
transplantation could be clinically applicable for the treatment of PD patients [45].
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The studies previously reported hypothesize that iPSC-derived neurons from PD patients can 
be very useful in the research of PD pathophysiology and to find new therapeutic targets for 
innovative drugs. Moreover, the possibility to differentiate iPSCs into nonneuronal cells, such 
as microglial and intestinal cells, will help to unravel the role of immunity response and the 
gastrointestinal disorder that affect PD patients.
2.2.3. iPSCs in amyotrophic lateral sclerosis
Amyotrophic lateral sclerosis (ALS) is the most prevalent motor neuron disease and is character-
ized by the progressive loss of upper and lower motor neurons (MNs), leading to muscle atro-
phy, paralysis, and finally death usually after 2–5 years from the first diagnosis [21]. Also for ALS 
the cause is still unknown, but in about 5–10% of cases, several genes are found mutated, among 
which are SOD1, TARDPB, and FUS [46]. Moreover, in 2013 the GGGGCC-hexanucleotide 
repeat expansion in C9orf72 locus was found in many familial and sporadic cases of ALS [47].
MNs derived from iPSCs are the most common neural cell type used in ALS involving the use 
of stem cell differentiation. For example, an increase in oxidative stress and in DNA damage 
was found in iPSC-derived C9ORF72 MNs, confirming that the reduction of oxidative stress 
could help to delay patients’ death [48]. Moreover, MNs derived from iPSCs with induced 
mutation in FUS (P525L) were used to investigate the transcriptome and microRNA, finding 
an alteration of both in pathways with implications for ALS pathogenesis [49]. The role of 
astrocytes was also investigated in both sporadic and VCP mutant patients, suggesting that 
in ALS patients, the co-culture between MNs and astrocytes causes alterations in both cell 
types [50, 51]. Moreover, the genetic correction allowed to study pathways implicated in ALS, 
like Bhinge and colleagues that found that the activation of AP1 drives neurodegeneration 
in genetic corrected SOD1 mutant MNs [52]. Small-molecule compounds that regulate IGF-2 
expression were found to increase MN resilience, screening the compounds in iPSC-derived 
MNs [53]. Another example is given by Egawa and colleagues that firstly generated and char-
acterized MNs from iPSCs of patients carrying TDP-43 mutations. They found some patho-
logical hallmark, such as short neurites and abnormal-insoluble TDP-43. Then, they tested 
trichostatin A, spliceostatin A, garcinol, and anacardic acid and found that the last one, an 
inhibitor of histone deacetylase, rescued the pathogenic abnormalities like TDP-43 mRNA [54]. 
All these researches suggest the increasing importance of iPSCs as model for drug screening.
These works suggest that MNs derived from iPSCs of mutated and sporadic ALS patients can 
be a helpful tool to study both disease mechanisms and drug screening. Several investigations 
can be done in iPSC-derived MN cellular models, e.g., oxidative stress, DNA damage, and tran-
scriptome. The co-culture between astrocytes and MNs can give information about how they 
interact with each other and whether this interaction could have a pathophysiologic role in ALS.
2.2.4. iPSCs in Huntington’s disease
Huntington’s disease (HD) is characterized by loss of neurons mainly in the caudate nucleus, 
the putamen, and the cerebral cortex with affection in a later stage of other areas, e.g., the 
hippocampus and hypothalamus [55]. Despite other neurodegenerative diseases, the cause 
of HD is well known; in fact it is an autosomal dominant genetic disorder caused by an 
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expansion mutation of the trinucleotide (CAG) repeat in the HTT (IT15) gene, encoding a 
350-kDa protein called Huntingtin (HTT) [56]. Even though the genetic cause is clear, the 
mechanisms through which mutant HTT results in the degeneration of some types of neurons 
are still unclear. Thus, studies on HD models are needed in order to discover treatments.
As the neurodegenerative diseases previously reported, also for HD, neurons differentiated 
from iPSCs of patients helped to understand the role of mutant HTT gene and the mecha-
nisms that lead to the pathology. For example, early molecular changes in intracellular signal-
ing, expression of oxidative stress proteins, and p53 pathway both in iPSCs and in neurons 
differentiated from them were reported [57]. Another study reported changes in neuronal 
development and adult neurogenesis, exploiting the iPSC capacity to model also embryonal 
development [58]. The generation of iPSCs from a patient that presents an expansion in the 
HTT gene without any symptom is very intriguing. The generation of iPSCs in an early stage 
of HD will allow to study the pathological process and the abnormal changes that lead to the 
pathology [59]. The possibility to differentiate iPSCs into neurons opened the possibility to 
discover new therapeutic targets, e.g., pre-mRNA trans-splicing modules [60]. Finally, the 
role of glial cells was investigated in several studies, among these who studied it were Hsiao 
and colleagues that reported that HD astrocytes provide less pericyte coverage by promoting 
angiogenesis and reducing the number of pericytes [61]. Finally, in a mouse cell model of HD, 
many but not all pathological hallmarks of HD were found. This result suggests that nonhu-
man iPSCs must be used carefully when translated into human pathology [62].
The researches previously reported highlight the importance to have a realistic model of the 
disease to study mechanisms that lead to neurodegeneration and iPSC-derived neurons that 
represent as a useful tool. They can be used also to perform a study of drug discovery and 
drug screening, to better understand the effect of chemicals in neurons. Moreover, the pos-
sibility to differentiate iPSCs in nonneuronal cells, such as astrocytes, helps to discover the 
role of glial cells in HD pathogenesis.
3. 3D bioprinting
The term bioprinting was used for the first time in 2009 by Mironov with the release of the 
first issue of the journal Biofabrication, a magazine that took its name from the eponymous 
term biofabrication. While the term biofabrication is intended to indicate natural processes 
such as biomineralization, the term bioprinting is defined by Guillemot in 2010 as [63, 64].
The use of computer-aided transfer processes for patterning and assembling living and non-
living materials with a prescribed 2D or 3D organization in order to produce bio-engineered 
structures serving in regenerative medicine, pharmacokinetic and basic cell biology studies.
3D bioprinting is an emerging technology, used for the manufacture and the generation 
of artificial tissues and organs [65], adding new approaches to tissue engineering (TE) and 
regenerative medicine, such as the manufacture of scaffold to support cells, as well as in situ 
deposition of cell suspensions [63]. Bioprinting technology has allowed to overcome several 
limits, such as the control of in vitro 3D biological structures and cellular distribution [66]. 
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Figure 2. On the top the most used printing processes are extrusion-based (performed by piston, pneumatic method, or 
screw), inkjet-based operated by a piezoelectric actuator, and laser-assisted (composed of an energy-absorbing slide and 
a donor slide that collect the discharged bioink droplets). On the bottom the complexity of the 3D bioprinted construct, 
composed of a natural biocompatible material (e.G., alginate), cells, functional peptides, and other biocompatible 
materials. (the image was taken from Axpe and Oyen [67]).
Bioprinting, through the use of hardware and software, has been used in particular for the 
design of three-dimensional structures, allowing the creation of “organoids” for biological 
and pharmacological studies, and to repair and replace human tissues.
3.1. Bioprinting and bioplotter techniques
Bioprinting can be distinguished on the basis of the bioink printing technique, allowing to 
change the printing processes according to the needs that the different cell types require: ink-
jet, laser, and extrusion (Figure 2) [65]. In addition to the specific printer characteristic, each 
bioplotter must have common functionalities. The most important is the presence of a robotic 
displacement system that can move along the three Cartesian axes, x, y, and, for the 3D char-
acteristics, z. Usually, the bioink is extruded from a dispenser, but it is possible to have more 
dispensers, permitting to have different bioinks in the same scaffold. One of the most recent 
techniques allows a coaxial extrusion, with a bioink that is surrounded by a second bioink. The 
sterility of the printout is usually guaranteed by the presence of sterile chamber with laminar 
flow system. If the bioplotter is quite small, this problem could be overcome by simply placing 
the bioprinter under a classic cellular hood. Finally, the presence of a dedicated software for the 
supply of bioink and for the high-resolution control of the design of the construct to be printed 
is essential [65].
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First, bioplotters that appeared on the market were intended for a purely industrial use, since 
they had a high price. The costs limited their development and related researches. With the 
advent of technology and knowledge of bioprinting, we have witnessed the birth of multiple 
models of bioplotters, each with characteristics that reflect the needs of the individual creator 
[12, 13], e.g., increasing the number of nozzles for simultaneous extrusion of several materials 
[68] and changing the type of technology that controls the nozzle.
3.1.1. Inkjet bioplotter
Inkjet bioplotter was the first technique used in the 1980s in offices and then for domestic 
use. It was readapted around the year 2000 to be used as a biological printer, replacing the 
normal ink with a bioink, containing cells and biocompatible materials [69]. Droplets of the 
biomaterial are extruded from very small orifices, deposited on a substrate, maintaining good 
cell dispersion, viability, and functionality, even with different cellular types [70]. The stream 
can be continuous, command-driven (drop on demand), and electrodynamic. Both piezoelec-
tric and thermal inkjet printers have been readapted for biological printing, offering many 
advantages in terms of simplicity, versatility, and material control, both in terms of quantity 
and speed in the printing process [71].
3.1.2. Laser technology
Laser-based direct writing was introduced in 1999 and is one of the most used laser-based 
bioprinting techniques [72]. The technique involves a layer with biological material (donor 
layer) and a layer that collect cells (acceptor layer) that are pushed by the laser through the 
first layer. The pulsation of the laser creates bubbles which in turn generate a shockwave, 
forcing the cells to pass from the donor layer to the acceptor layer. This technique allows to 
have a good resolution but has some disadvantages, such as irreversible damage to the cells 
because of the heat and light generated by the laser [65].
3.1.3. Extrusion-based bioprinter
The advent of TE has allowed extrusion technology to be thoroughly studied and applied to 
the field of bioprinting, for the generation of living tissues. Extrusion technique includes a com-
bination of different delivery systems combined with an automatic robotic system for extru-
sion and 3D printing [73]. Deposition of the material takes place through extrusion to form a 
cylindrical filament made of a biocompatible gelatinous material, in which the cells are encap-
sulated, maintaining the desired three-dimensional structure [74]. This type of extrusion can 
be pneumatic or mechanical. Mechanical extrusion involves the use of a piston, which guides 
the deposit of the material allowing a good flow control through the nozzle, or a screw, which 
allows the extrusion of more viscous substances, but which can cause leakage of pressure, 
causing damage to cells. This technique also has some limits, particularly during the develop-
ment of the biomaterial which must have the right viscosity to be extruded and the ability to 
be easily homogenized with cell suspension and to maintain three-dimensional structure [65].
3.2. Hydrogel and bioink
One of the fundamental elements that characterize the bioprinting process is the development 
of biomaterial, which must have specific characteristics: biocompatibility, printability, and 
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ability to maintain a three-dimensional structure once printed and maintained in culture [65]. 
The main feature of the hydrogel, biocompatible material used as a three-dimensional support 
for cell growth, is the ability to be extremely hydrophilic, making it an excellent candidate in 
terms of biocompatibility for its use in bioprinting. It was initially used in TE because it was 
able to simulate the extracellular matrix, guarantying cell growth and communication [75]. 
Biomaterials are divided, According to their derivation, biomaterials are divided in natural or 
synthetic compunds. There are naturally derived polymers such as sodium alginate, gelatin, 
collagen, chitosan, fibrin, and GelMA [76–78] and synthetic polymers such as Pluronic®, poly-
ethylene glycol (PEG), and polyurethanes [79, 80]. Over time, it has been seen how the natural 
compounds are more performing when placed in contact with the cells than the synthetic 
ones. Several cell types associated with different biomaterials to compose the bioink have 
already been used in several research areas, where cellular viability and motility have been 
demonstrated, as well as a spatial organization similar to in vivo tissue [81]. To create a new 
biomaterial, we must consider different physical, mechanical, and biological characteristics 
that are close to the tissue we want to recreate. Thus, researchers tend to create a combination 
of biomaterials for each cell type, and with well-defined printability specifications, so as to 
make the process as standardized and reproducible as possible, despite being a very open 
field and full of new developments. New-generation bioinks are now able to maintain each 
of these characteristics, thus improving the success in terms of bioprinting. All this is possible 
if particular attention is paid to the following chemical, physical, and biological properties: 
rheological studies (viscosity, thinning, viscoelasticity), biofunctional analysis, biodegrada-
tion, and polymerization (cytocompatibility, cell adhesion, migration, proliferation, and dif-
ferentiation) [82]. One of the most important features that has different biomaterials is the 
ability to cross-link once the bioink has been printed, reticulating the bioink in which cells are 
encapsulated, without affecting the viability, the differentiation, and the capacity of migration 
[83]. The ability to polymerize depends on the material used; for example, collagen needs 
chemical cross-link, through covalent bonds that bind free amines or carboxylic groups of col-
lagen that is able to reticulate, also through a biological process, and through the interaction 
with transglutaminase. Other compounds, such as sodium alginate, use an ionic cross-link: 
divalent cations such as Ca2+ bind to two sodium alginate residues, cross-linking the struc-
ture. UV radiation is a very promising cross-link technique given its reaction speed but with 
many questions regarding the possible damage induced to the cells included in the material. 
Other materials, such as gelatin and agarose, are heat-sensitive, so they are used during the 
printing process at the melting temperature and then stiffened with cooling [84–87]. One of 
the most common types of bioink used in bioprinting techniques is the so-called cell-laden 
hydrogel, which includes natural hydrogels such as agarose, sodium alginate, chitosan, col-
lagen, gelatin, fibrin, and hyaluronic acid and synthetic hydrogels such as Pluronic® and 
PEG. Hydrogels can be used with the most common bioplotter that mount different printing 
techniques, allowing the creation of bioinks that combine the advantages of the natural mate-
rial with the advantages of synthetic materials [88]. Recent findings have shown also the pos-
sibility to transfect cells with target DNA or plasmid, directly during the bioprinting process 
[80]. A new promising method to develop bioinks is the base on decellularized extracellular 
matrix. This kind of bioink consists in eliminating cells from a tissue of interest, keeping intact 
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the extracellular matrix that is then pulverized and subsequently used as bioink once dis-
solved in a saline buffer. Finally, the cell suspension bioinks, characterized by a print that 
does not have a support material, like a scaffold, are also very common. It uses aggregates of 
cells in culture medium, placed in mono- or multicell spheres [73]. This technique is based on 
the liquidity of the tissue and its fusion, such as to allow cells to assemble, merge, and create 
cell-to-cell interconnections [89, 90]. Organovo was the first medical research company that 
used this technique to create functional human tissues. They developed a liver model using 
parenchyma cells and an extrusion printer of their own creation [91].
4. 3D bioprinting and neurodegeneration
In the last decade, the possibility of replacing dead cells in degenerative processes affecting the 
central nervous system opened the way for a more intense and accurate study of stem cells and 
their possibility of replacing damaged tissue [92]. It was also thought to exploit the ability of 
stem cells to secrete cytokines and growth factors, offering benefits such as anti-inflammatory 
effects, protection of neural cells, and endogenous recovery systems. Transplanting these cells 
into damaged sites presents various problems such as low cell survival and limited engraft-
ment [93]. To minimize these problems, it was decided to use three-dimensional scaffold print-
ing that mimics the complexity both from the biological and functional points of view of the 
tissue to be replaced [94].
The manufacture of three-dimensional prefabricated scaffolds has already given positive results 
in the treatment and repair of spinal and nerve damage but with a great limitation in terms of 
control of the external shape of the scaffold and of its internal architecture [95, 96]. These prob-
lems have been overcome with the 3D bioprinting, which leaves the operator complete freedom 
regarding the shape, the material, and its internal architecture. The recent developments in the 
field of 3D bioprinting are mostly aimed to the field of regenerative medicine, to respond to the 
growing demand for tissues and organs for transplants, arriving only later for this technology 
to be applied to basic scientific research. Until now only few studies have focused on using 3D 
printing applied to the creation of neural tissue compared to other widely studied tissues such 
as the skin, bones, heart tissue, and cartilaginous structures [97]. The few studies published so 
far, in which they use nerve cells in 3D printing processes [98, 99], show a poor characterization 
of bioinks to be used for nerve cells, due to the delicacy of the tissue to be recreated and of the 
characteristics necessary for the optimal growth of the nervous tissue [94]. Recently, researchers 
also think that the nervous tissue printed in 3D may be used for the neural regeneration, a huge 
possibility in the field of neurodegeneration to replace degenerated neural tissue [78, 80].
The creation of nerve tissue by bioprinting is also used for pharmacological studies, for toxi-
cological screening, and for basic research. It is necessary to underline how this field is still in 
its infancy and how it is necessary to validate this model for the applications described up to 
now, to be sure that the model completely recapitulates the pathophysiology that we want to 
investigate with this tool [94] in particular with regard to neurodegenerative diseases.
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5. Conclusions
In the last decade, two groundbreaking discoveries, i.e., somatic cell reprogramming into iPSCs 
and 3D bioprinting, changed the way to modeling diseases, in particular for those pathologies 
which are hard to study in simple cell cultures, such as neurodegenerative diseases. The first 
one is permitted to obtain neural cell cultures in few months starting from adult somatic cells, 
like fibroblasts and PBMCs, while 3D bioprinting consists in the print of hydrogel and cells, to 
generate models that imitate tissue characteristics. While iPSCs are differentiated into neurons 
in many papers for disease modeling, 3D bioprinting is actually used for few tissues, like the 
cartilage, bone, and heart. Neural 3D cell cultures are still in development, there are no target 
bioinks, and the studies that combine neuronal cells and 3D bioprinting are more complicated 
than other tissues because of the fragility of such cells. Despite this hurdle, the possibility to 
create an in vitro neural tissue would open many fields of research that today are unreachable, 
first of all the opportunity to study the 3D spatial connection between different neuronal popu-
lations and how they communicate with each other. In combination with iPSC technology, we 
can create a physiological model to understand physiological and pathological mechanisms 
and to better understand mechanisms underlying neurodegenerative diseases.
Finally, the combination between 3D bioprinting and iPSC technology will open not only new 
possibilities in many fields, drug screening, replacing expensive in vivo experiments, and 
overcoming animal models’ issues, but also personalized medicine thanks to the use of cells 
derived from patients. More intriguingly, the generation of a 3D neural tissue composed of 
patient’s cell will allow the so-called neuro-regeneration, opening the possibility to replace a 
degenerated tissue.
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